Table 1 Clinical and biological features of patients

From: The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia

 

Population (n = 522)

M-noCK (n = 240)

U-CK1 (n = 213)

CK2 (n = 69)

p values

Gender

  Female

203 (39%)

88 (37%)

87 (41%)

28 (41%)

0.6298

  Male

319 (61%)

152 (63%)

126 (59%)

41 (59%)

 

Age (years)

  Median ± sd

65 ± 10

59 ± 11

65 ± 12

70 ± 10

0.0053

Binet stage

  A

396 (76%)

164 (69%)

189 (89%)

43 (62%)

<0.0001

  B

91 (17%)

66 (27%)

8 (4%)

17 (25%)

 

  C

35 (7%)

10 (4%)

16 (7%)

9 (13%)

 

β2-microglobulin (mg/L)

  Median ± sd

2.92 ± 1.53

2.47 ± 1.55

3.17 ± 1.34

3.27 ± 1.78

<0.0001

CD38a

  <30%

388 (74%)

207 (88%)

140 (67%)

41 (62%)

<0.0001

  ≥30%

121 (23%)

27 (12%)

69 (33%)

25 (38%)

 

IGHV status

  M-IGHV

279 (53%)

240 (100%)

15 (7%)

24 (35%)

n.a.

  U-IGHV

243 (47%)

0 (0%)

198 (93%)

45 (65%)

 

FISHa

  Normal

153 (29%)

86 (38%)

59 (28%)

8 (12%)

<0.0001

  13q

196 (38%)

122 (54%)

56 (27%)

18 (26%)

 

  +12

76 (15%)

17 (8%)

52 (25%)

7 (10%)

 

  11q

50 (10%)

4 (2%)

33 (16%)

13 (19%)

 

  17p

36 (7%)

3 (1%)

10 (5%)

23 (33%)

 

TP53a

  Normal

469 (90%)

229 (97%)

197 (92%)

43 (62%)

<0.0001

  Abnormal

48 (9%)

6 (3%)

16 (8%)

26 (38%)

 

N. Chr. abn.

  0

167 (32%)

117 (49%)

50 (24%)

0 (0%)

<0.0001

  1–2

258 (49%)

123 (51%)

135 (63%)

0 (0%)

 

  3–4

53 (10%)

0 (0%)

25 (12%)

28 (41%)

 

   ≥5

44 (9%)

0 (0%)

3 (1%)

41 (59%)

 
  1. sd standard deviation, M-IGHV mutated IGHV gene, U-IGHV unmutated IGHV gene, N. Chr. abn. number of chromosomal abnormalities, CK complex karyotype, M-noCK M-IGHV without CK, U-CK1 U-IGHV and/or type 1 CK, CK2 type 2 CK. n.a. not applicable
  2. aMissing data  =  3% about CD38 expression, 1% cytogenetic by FISH and 1% for TP53 abnormalities (including deletions and/or mutations)
Back to article page